417 related articles for article (PubMed ID: 25887188)
21. Advances in biology and therapy of multiple myeloma.
Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
[TBL] [Abstract][Full Text] [Related]
22. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
[TBL] [Abstract][Full Text] [Related]
23. IGFBP7 regulates the osteogenic differentiation of bone marrow-derived mesenchymal stem cells via Wnt/β-catenin signaling pathway.
Zhang W; Chen E; Chen M; Ye C; Qi Y; Ding Q; Li H; Xue D; Gao X; Pan Z
FASEB J; 2018 Apr; 32(4):2280-2291. PubMed ID: 29242275
[TBL] [Abstract][Full Text] [Related]
24. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
Nojima M; Maruyama R; Yasui H; Suzuki H; Maruyama Y; Tarasawa I; Sasaki Y; Asaoku H; Sakai H; Hayashi T; Mori M; Imai K; Tokino T; Ishida T; Toyota M; Shinomura Y
Clin Cancer Res; 2009 Jul; 15(13):4356-64. PubMed ID: 19549772
[TBL] [Abstract][Full Text] [Related]
25. High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma.
Song YF; Xu R; Zhang XH; Chen BB; Chen Q; Chen YM; Xie Y
J Clin Pathol; 2006 Sep; 59(9):947-51. PubMed ID: 16489177
[TBL] [Abstract][Full Text] [Related]
26. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H
J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956
[TBL] [Abstract][Full Text] [Related]
27. Circulating cell-free DNA of methylated insulin-like growth factor-binding protein 7 predicts a poor prognosis in hepatitis B virus-associated hepatocellular carcinoma after hepatectomy.
Li F; Qiao CY; Gao S; Fan YC; Chen LY; Wang K
Free Radic Res; 2018 Apr; 52(4):455-464. PubMed ID: 29463155
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.
Tatetsu H; Ueno S; Hata H; Yamada Y; Takeya M; Mitsuya H; Tenen DG; Okuno Y
Cancer Res; 2007 Jun; 67(11):5328-36. PubMed ID: 17545613
[TBL] [Abstract][Full Text] [Related]
29. IGFBP7 is associated with poor prognosis in oesophageal adenocarcinoma and is regulated by promoter DNA methylation.
Smith E; Ruszkiewicz AR; Jamieson GG; Drew PA
Br J Cancer; 2014 Feb; 110(3):775-82. PubMed ID: 24357797
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
Fonseca R; Van Wier SA; Chng WJ; Ketterling R; Lacy MQ; Dispenzieri A; Bergsagel PL; Rajkumar SV; Greipp PR; Litzow MR; Price-Troska T; Henderson KJ; Ahmann GJ; Gertz MA
Leukemia; 2006 Nov; 20(11):2034-40. PubMed ID: 17024118
[TBL] [Abstract][Full Text] [Related]
31. Insulin-like growth factor binding protein-7 (IGFBP7) blocks vascular endothelial cell growth factor (VEGF)-induced angiogenesis in human vascular endothelial cells.
Tamura K; Hashimoto K; Suzuki K; Yoshie M; Kutsukake M; Sakurai T
Eur J Pharmacol; 2009 May; 610(1-3):61-7. PubMed ID: 19374835
[TBL] [Abstract][Full Text] [Related]
32. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.
Noll JE; Vandyke K; Hewett DR; Mrozik KM; Bala RJ; Williams SA; Kok CH; Zannettino AC
J Hematol Oncol; 2015 Oct; 8():106. PubMed ID: 26445238
[TBL] [Abstract][Full Text] [Related]
33. Insulin-like growth factor-binding protein 7 regulates keratinocyte proliferation, differentiation and apoptosis.
Nousbeck J; Sarig O; Avidan N; Indelman M; Bergman R; Ramon M; Enk CD; Sprecher E
J Invest Dermatol; 2010 Feb; 130(2):378-87. PubMed ID: 19710688
[TBL] [Abstract][Full Text] [Related]
34. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma.
Tshuikina M; Jernberg-Wiklund H; Nilsson K; Oberg F
Exp Hematol; 2008 Dec; 36(12):1673-1681. PubMed ID: 18922617
[TBL] [Abstract][Full Text] [Related]
36. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.
Mylin AK; Rasmussen T; Johansen JS; Knudsen LM; Nørgaard PH; Lenhoff S; Dahl IM; Johnsen HE;
Eur J Haematol; 2006 Nov; 77(5):416-24. PubMed ID: 16930142
[TBL] [Abstract][Full Text] [Related]
37. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
38. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.
Shaughnessy J
Hematology; 2005; 10 Suppl 1():117-26. PubMed ID: 16188652
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic Downregulation and Growth Inhibition of IGFBP7 in Gastric Cancer.
Kim J; Kim WH; Byeon SJ; Lee BL; Kim MA
Asian Pac J Cancer Prev; 2018 Mar; 19(3):667-675. PubMed ID: 29580038
[TBL] [Abstract][Full Text] [Related]
40. BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia.
Heesch S; Schlee C; Neumann M; Stroux A; Kühnl A; Schwartz S; Haferlach T; Goekbuget N; Hoelzer D; Thiel E; Hofmann WK; Baldus CD
Leukemia; 2010 Aug; 24(8):1429-36. PubMed ID: 20535151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
